Efficacy and safety of GLP-1 receptor agonists in the management of obstructive sleep apnea in individuals without diabetes: A systematic review and meta-analysis of randomized, placebo-controlled trials

GLP-1 receptor agonist treatment reduced the apnea-hypopnea index by 16.6 events per hour compared to placebo.

• Three randomized controlled trials were analyzed to evaluate the effects of GLP-1 receptor agonists in individuals with obstructive sleep apnea and elevated body weight.
• Pooled results indicated a significant reduction in the severity of obstructive sleep apnea as measured by the apnea-hypopnea index.
• GLP-1 receptor agonists were associated with a higher frequency of adverse events compared to placebo.
• The odds of experiencing adverse events increased with GLP-1 RA treatment, suggesting a potential risk for users.
• Further long-term studies are needed to better understand the benefits and safety of GLP-1 receptor agonists in managing obstructive sleep apnea.

AI simplified